NJA-730

N/A

Report date: 2022/07/19 15:13:10
NME

Base Information

Drug NameNJA-730
Drug Alias NameNJA-730NJA-730aNJA-730b
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 inhibitorsImmunosuppressantsRNA interference
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNapajen Pharma
China Registration ClassN/A

Develop Information

Active CompaniesNapajen Pharma
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A